Fig. 5

Confirmation of EFEMP2-EGFR binding and the effect of down or up expression of EFEMP2 on ERK1/2/c-Jun pathway or the JNK/c-Jun pathway. a By co-IP assay, the EGF-related protein EFEMP2 was confirmed to bind to EGFR. b By western blot, EFEMP2 knockdown significantly reduced the expression and phosphorylation level of EGFR, ERK1/2 and c-Jun, however, the expression and phosphorylation level of JNK remained unchanged. c Conversely, EFEMP2 overexpression increased EGFR, ERK1/2 and c-Jun expression and their phosphorylation levels, but had no effect on the expression and phosphorylation level of JNK. Western blot was used to analyze the expression and phosphorylation level of ERK1/2/c-Jun pathway and PD-L1 expression in (d) ES2 and (e) OVCAR-3 EX after trametinib (0 μmol/l, 4 μmol/l, 8 μmol/l, and 12 μmol/l) treatment. The transwell chamber was used to detect the migration and invasion ability of (f) ES-2 and (g) OVCAR-3 EX cells after trametinib (0 μmol/l, 4 μmol/l, 8 μmol/l, and 12 μmol/l) treatment. Magnification × 200